Patterson Companies Inc header image

Patterson Companies Inc

PDCO

Equity

ISIN US7033951036 / Valor 1896660

NASDAQ (2024-09-16)
USD 21.74-0.59%

Patterson Companies Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Patterson Companies Inc is a company that specializes in providing products, technologies, services, and business solutions to the animal and oral health markets. With a comprehensive portfolio and distribution network, the company is known for its dedication to serving these specific industries. The company's success is attributed to its passionate and focused team of professionals who work tirelessly to meet the needs of their customers in the animal and oral health sectors.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (20.08.2024):

Net Sales

Patterson Companies Inc. reported consolidated net sales of $1.72 billion for the fourth quarter of fiscal 2024, marking a slight increase of 0.1 percent compared to the same period last year. Internal sales, adjusted for currency translation and other factors, decreased by 0.5 percent year-over-year.

Net Income

For the fourth quarter of fiscal 2024, Patterson Companies Inc. reported net income attributable to the company of $67.0 million, or $0.74 per diluted share. This is a decrease from the $75.0 million, or $0.77 per diluted share, reported in the fourth quarter of fiscal 2023.

Dental Segment

The Dental segment of Patterson Companies Inc. reported net sales of $657.8 million for the fourth quarter of fiscal 2024. Internal sales of dental consumables increased by 3.7 percent year-over-year, while internal sales of equipment and value-added services decreased by 11.9 percent and 11.0 percent, respectively.

Animal Health Segment

In the fourth quarter of fiscal 2024, the Animal Health segment reported net sales of $1.06 billion. Internal sales in this segment grew by 2.5 percent year-over-year, driven by a 2.5 percent increase in consumables and a 15.0 percent increase in value-added services, despite a 4.0 percent decline in equipment sales.

Fiscal 2025 Guidance

Patterson Companies Inc. has issued its fiscal 2025 earnings guidance, projecting GAAP earnings to be in the range of $2.00 to $2.10 per diluted share. Non-GAAP adjusted earnings are expected to be between $2.33 and $2.43 per diluted share, excluding deal amortization expenses and other adjustments.

Summarized from source with an LLMView Source

Key figures

-23.3%1Y
-30.8%3Y
16.2%5Y

Performance

36.3%1Y
32.3%3Y
39.7%5Y

Volatility

Market cap

1928 M

Market cap (USD)

Daily traded volume (Shares)

230,037

Daily traded volume (Shares)

1 day high/low

22.11 / 21.3

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Xvivo Perfusion AB
Xvivo Perfusion AB Xvivo Perfusion AB Valor: 19661174
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.40%SEK 508.00
Calliditas Therapeutics AB
Calliditas Therapeutics AB Calliditas Therapeutics AB Valor: 42290712
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.10%SEK 206.40
Nihon Chemical Research KK
Nihon Chemical Research KK Nihon Chemical Research KK Valor: 785030
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.45%JPY 660.00
Oncopeptides AB
Oncopeptides AB Oncopeptides AB Valor: 35671972
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.10%SEK 2.10
KK B.M.L
KK B.M.L KK B.M.L Valor: 789977
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.68%JPY 2,642.00
Kissei Yakuhin Kogyo KK
Kissei Yakuhin Kogyo KK Kissei Yakuhin Kogyo KK Valor: 764769
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.14%JPY 3,475.00
Hasegawa Kouryou KK
Hasegawa Kouryou KK Hasegawa Kouryou KK Valor: 372531
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.35%JPY 3,010.00
Pharma Mar SA
Pharma Mar SA Pharma Mar SA Valor: 56130572
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.13%EUR 42.00
Novartis Inc
Novartis Inc Novartis Inc Valor: 567514
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.12%USD 116.95
GSK PLC
GSK PLC GSK PLC Valor: 120042705
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.26%USD 43.55